scholarly journals Fibroblast Growth Factor Basic Form Measurement

2020 ◽  
Author(s):  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth ◽  
Basic Form ◽  
Fibroblast Growth Factor Basic

Diffusion of Fibroblast Growth Factor from a Plaster of Paris Carrier

1991 ◽  
Vol 252 ◽  
Author(s):  
S. Rosenblum ◽  
S. Frenkel ◽  
J. Ricci ◽  
H. Alexander
Keyword(s):  
Endothelial Cells ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Target Tissue ◽  
Fibroblast Growth ◽  
Basic Form ◽  
Cortical Cells ◽  
Ovarian Granulosa Cells ◽  
Acidic Form ◽  
Adrenal Cortical Cells

Fibroblast growth factor (FGF) is a polypeptide found in two forms: basic and acidic. The basic form is produced by many more types of cells than the acidic form, although both bind to the same receptor. These proteins act on a variety of mesodermally and ectodermally derived cells, including chondrocytes, glial cells, myoblasts, endothelial cells, cornea and lens epithelia, adrenal cortical cells, ovarian granulosa cells, periosteal fibroblasts, and osteoblasts. Basic FGF was chosen for the present study for a variety of reasons. First, it has significant cross-species homology, with 98.7% correlation between human and both bovine and avian FGF. Less conservation has been observed in the acidic form. In addition, the basic form has been shown to be 30- to 100-fold more potent, depending on the target tissue.

scholarly journals Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders

1998 ◽  
Vol 82 (2) ◽  
pp. 181-185 ◽  
Author(s):  
L Cassidy ◽  
P Barry ◽  
C Shaw ◽  
M J Duffy ◽  
S Kennedy
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Platelet Derived Growth Factor ◽  
Fibroblast Growth ◽  
Fibroblast Growth Factor Basic

Amnionmembransuspension und autologes Serum – spielt der Inhalt eine Rolle für die Wundheilung?

2017 ◽  
Vol 234 (08) ◽  
pp. 1015-1018
Author(s):  
T. Stachon ◽  
M.-F. Wu ◽  
M. Bischoff ◽  
M. Huber ◽  
A. Langenbucher ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Fibroblast Growth Factor ◽  
Interleukin 6 ◽  
Fibroblast Growth ◽  
Epidermal Growth ◽  
Fibroblast Growth Factor Basic

ZusammenfassungAutologes Serum (AS) und Amnionmembrantransplantate (AMT) werden für eine Vielzahl von Oberflächenerkrankungen des Auges eingesetzt. Die Amnionmembrantransplantation ist immer mit einem operativen Eingriff verbunden. Für die Patienten wäre es von Vorteil, wenn durch die Applikation von Augentropfen, die aus Amniongewebehomogenat (AMH) oder Amnionmembransuspension (AMS) gewonnen würden, eine Operation vermieden werden könnte. In einer früheren Studie haben wir nachgewiesen, dass Epidermal Growth Factor (EGF), Fibroblast Growth Factor basic (bFGF), Interleukin-6 (IL-6) und IL-8 in AMS freigesetzt wird. Die EGF- und bFGF-Konzentrationen in den AMS lagen jedoch im Durchschnitt um das 1,7–17-Fache niedriger als in den AMH, und in den AMH konnte im Vergleich zur AMS kein IL-6 und IL-8 nachgewiesen werden. 100 % AMS, 15 und 30 % AMH verlangsamten die Proliferation humaner Epithelzellen im Vergleich zur Kontrolle (p = <0,002 für alle), während 15 und 30 % AMS keinen Einfluss auf die Proliferation hatten. Im Vergleich zu den Kontrollen wurde die Migrationsrate unter Verwendung von 15 und 30 % AMS gesteigert (p < 0,001), zeigte aber keinen Unterschied bei einem Einsatz von 15 und 30 % AMH (p = 0,153 und p = 0,083). Die Proliferationsrate wurde durch den Einsatz von 15 % humanem Serum gegenüber 30 % humanem Serum gesteigert (p < 0,001). Humane korneale Epithelzelllinien (HCECs) migrierten schneller mit einer humanen Serumkonzentration von 30 % im Vergleich zu 5 % humanem Serum (p < 0,01). Zusammengefasst zeigten der Einsatz von 15 und 30 % AMS sowie der Einsatz von 15 und 30 % AS die vorteilhafteste Wirkung auf humane Epithelzellen. Jedoch muss bei der Gabe von AS- und AMS-Augentropfen bedacht werden, dass die individuelle Konzentration der Wachstumsfaktoren einer großen Schwankungsbreite unterliegt.

Treatment of bronchial fistula after extraplural pneumonectomy using flexible bronchoscopy with the administration of OK432, fibroblast growth factor basic and fibrin glue sealant

2020 ◽  
Vol 68 (12) ◽  
pp. 1562-1564
Author(s):  
Nobuyuki Kondo ◽  
Masaki Hashimoto ◽  
Teruhisa Takuwa ◽  
Seiji Matsumoto ◽  
Yoshitomo Okumura ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibrin Glue ◽  
Flexible Bronchoscopy ◽  
Fibroblast Growth ◽  
Bronchial Fistula ◽  
Fibroblast Growth Factor Basic ◽  
Fibrin Glue Sealant

scholarly journals 3D Bioprinting Mesenchymal Stem Cell-Derived Neural Tissues Using a Fibrin-Based Bioink

Biomolecules ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1250
Author(s):  
Milena Restan Perez ◽  
Ruchi Sharma ◽  
Nadia Zeina Masri ◽  
Stephanie Michelle Willerth
Keyword(s):  
Stem Cells ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Disease Modeling ◽  
3D Bioprinting ◽  
Fibroblast Growth ◽  
Class Iii ◽  
Fibroblast Growth Factor 8 ◽  
Neural Tissues ◽  
Fibroblast Growth Factor Basic

Current treatments for neurodegenerative diseases aim to alleviate the symptoms experienced by patients; however, these treatments do not cure the disease nor prevent further degeneration. Improvements in current disease-modeling and drug-development practices could accelerate effective treatments for neurological diseases. To that end, 3D bioprinting has gained significant attention for engineering tissues in a rapid and reproducible fashion. Additionally, using patient-derived stem cells, which can be reprogrammed to neural-like cells, could generate personalized neural tissues. Here, adipose tissue-derived mesenchymal stem cells (MSCs) were bioprinted using a fibrin-based bioink and the microfluidic RX1 bioprinter. These tissues were cultured for 12 days in the presence of SB431542 (SB), LDN-193189 (LDN), purmorphamine (puro), fibroblast growth factor 8 (FGF8), fibroblast growth factor-basic (bFGF), and brain-derived neurotrophic factor (BDNF) to induce differentiation to dopaminergic neurons (DN). The constructs were analyzed for expression of neural markers, dopamine release, and electrophysiological activity. The cells expressed DN-specific and early neuronal markers (tyrosine hydroxylase (TH) and class III beta-tubulin (TUJ1), respectively) after 12 days of differentiation. Additionally, the tissues exhibited immature electrical signaling after treatment with potassium chloride (KCl). Overall, this work shows the potential of bioprinting engineered neural tissues from patient-derived MSCs, which could serve as an important tool for personalized disease models and drug-screening.

IGF-binding protein-6 is involved in growth inhibition in SH-SY5Y human neuroblastoma cells: its production is both IGF- and cell density-dependent

1997 ◽  
Vol 152 (2) ◽  
pp. 221-227 ◽  
Author(s):  
S Babajko ◽  
P Leneuve ◽  
C Loret ◽  
M Binoux
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Cell Density ◽  
Neuroblastoma Cells ◽  
Fibroblast Growth ◽  
Human Neuroblastoma ◽  
Igf System ◽  
Igf I ◽  
Igf Binding ◽  
Fibroblast Growth Factor Basic

Abstract The IGF system is involved in the growth and differentiation of neuroblastoma cells, but the precise roles played by the IGF-binding proteins (IGFBPs) remain unknown. We have examined the expression and functions of IGFBPs produced by the neuroblastoma cell line, SHSY5Y, in the presence of: insulin, IGF-I, IGF-II, des(1–3)IGF-I (an IGF-I analogue with weak affinity for IGFBPs), acidic fibroblast growth factor, basic fibroblast growth factor, or nerve growth factor. Under basal conditions, SH-SY5Y cells in serum-free medium secreted IGF-II, and traces of IGF-I, IGFBP-2 and IGFBP-4. After 24 h of culture, comparative mitogenic potencies were: des(1–3)IGF-I>IGF-1>IGF-II>insulin. After 48 h, when IGFBP-2 and IGFBP-4 concentrations in the culture media had increased, des(1–3)IGF-I remained the most active, but the activity of insulin now equalled or exceeded that of IGF-I and IGF-II. This suggests a negative feedback mechanism involving partial sequestration of IGF-I and IGF-II by IGFBP-2 and IGFBP-4. At high cell density and with high concentrations of IGF-I, des(1–3)IGF-I (40 ng/ml) or IGF-II (80 ng/ml), the mitogenic activities of the IGFs diminished concomitantly with the appearance in the culture medium of an additional IGFBP identified as IGFBP-6, whose production depended on activation of the type 1 IGF receptor. These findings suggest that IGFBP-6 contributes as an autocrine inhibitor in the regulation of growth by the IGF system in these neuroblastoma cells. Journal of Endocrinology (1997) 152, 221–227

Sign in / Sign up

Export Citation Format

Share Document